{"classes":[{"categories":[{"measurements":[{"comment":"Not calculable/estimable due to low number of participants with events","groupId":"OG000","lowerLimit":"51.3","upperLimit":"NA","value":"69.6"},{"comment":"Not calculable/estimable due to low number of participants with events","groupId":"OG001","lowerLimit":"57.2","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"OS is defined as the number of days from the date of first dose to the date of death for all dosed participants. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. OS was estimated using Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts","id":"OG000","title":"ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts"},{"description":"Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts","id":"OG001","title":"ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts"}],"paramType":"MEDIAN","populationDescription":"All participants in the Main and Expansion Cohorts who received at least one dose of venetoclax","reportingStatus":"POSTED","timeFrame":"At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}